Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 919-932
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.919
Construction of an immune-related gene signature for overall survival prediction and immune infiltration in gastric cancer
Xiao-Ting Ma, Xiu Liu, Kai Ou, Lin Yang
Xiao-Ting Ma, Xiu Liu, Kai Ou, Lin Yang, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Ma XT designed the article form and wrote the manuscript; Ou K and Liu X consulted and browsed the literature; Yang L revised the manuscript and provided the funding. All authors read and approved the final manuscript.
Supported by Beijing CSCO Clinical Oncology Research Foundation, No. Y-HH202102-0308.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences.
Informed consent statement: As the study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lin Yang, Doctor, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. linyangcicams@126.com
Received: September 7, 2023
Peer-review started: September 7, 2023
First decision: December 5, 2023
Revised: December 16, 2023
Accepted: February 2, 2024
Article in press: February 2, 2024
Published online: March 15, 2024
Core Tip

Core Tip: We ultimately obtained an Immune Related Signature based on 10 genes, including 9 risk genes (LCN1, LEAP2, TMSB15A mRNA, DEFB126, PI15, IGHD3-16, IGLV3-22, CGB5, GLP2R) and 1 protective gene (LGR6). Kaplan-Meier survival analysis, ROC analysis and risk curve confirmed that the risk model has good predictive ability. Multivariate COX analysis showed that age, stage and risk score were independent prognostic factors. Patients in the low-risk group had higher tumor mutation burden and immunophenotype score, which can be used to predict immune checkpoint inhibitor response. Both cytotoxic T lymphocyte antigen4+ and programmed death 1+ patients with lower risk scores were more sensitive to immunotherapy.